ICS-283: a system for targeted intravenous delivery of siRNA

被引：17

作者：

Schiffelers, Raymond M. ^{[1
]}

Storm, Gert ^{[1
]}

机构：

[1] Utrecht Inst Pharmaceut Sci, Dept Pharmaceut, NL-3508 TB Utrecht, Netherlands

来源：

EXPERT OPINION ON DRUG DELIVERY | 2006年 / 3卷 / 03期

关键词：

angiogenesis; cationic polymers; DNA; small interfering RNA; sterically stabilised nanoparticles; targeted drug delivery;

D O I：

10.1517/17425247.3.3.445

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

ICS-283 was developed within Intradigm Corporation as a system that is designed for the systemic delivery of therapeutic small interfering (siRNA) to sites of pathological angiogenesis. The non-viral siRNA delivery system is based on synthetic nanoparticles, known as TargeTran(TM) (Intradigm Corporation), which functions as a broad-platform technology to deliver siRNA to specific target cells in diseased tissues. The system is constructed to incorporate different functionalities that address critical needs for successful nucleic acid delivery. The TargeTran synthetic vector is a self-assembling, layered nanoparticle that protects and targets siRNA to specific cell types in pathological tissues. At present, ICS-283 is the only antiangiogenic siRNA delivery system that is designed for intravenous administration to treat angiogenesis-driven diseases.

引用

页码：445 / 454

页数：10

共 53 条

[11] VEGF as a therapeutic target in cancer [J].

Ferrara, N .

ONCOLOGY, 2005, 69 :11-16

[12] Role of angiogenesis in tumor growth and metastasis [J].

Folkman, J .

SEMINARS IN ONCOLOGY, 2002, 29 (06) :15-18

[13]

Gold L, 1995, Harvey Lect, V91, P47

[14] Potocytosis and cellular exit of complexes as cellular pathways for gene delivery by polycations [J].

Grosse, S ;

Aron, Y ;

Thévenot, G ;

François, D ;

Monsigny, M ;

Fajac, I .

JOURNAL OF GENE MEDICINE, 2005, 7 (10) :1275-1286

[15] Pursuing the leadlikeness concept in pharmaceutical research [J].

Hann, MM ;

Oprea, TI .

CURRENT OPINION IN CHEMICAL BIOLOGY, 2004, 8 (03) :255-263

[16]

Henry S P, 2001, Curr Opin Investig Drugs, V2, P1444

[17]

Herbst Roy S, 2005, Cancer Chemother Biol Response Modif, V22, P225

[18]

Horton MA, 1999, EXP NEPHROL, V7, P178

[19] Reaction parameters of targeted gene repair in mammalian cells [J].

Hu, YL ;

Parekh-Olmedo, H ;

Drury, M ;

Skogen, M ;

Kmiec, EB .

MOLECULAR BIOTECHNOLOGY, 2005, 29 (03) :197-210

[20] Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor pathway genes - Therapeutic strategy for herpetic stromal keratitis [J].

Kim, B ;

Tang, QQ ;

Biswas, PS ;

Xu, J ;

Schiffelers, RM ;

Xie, FY ;

Ansari, AM ;

Scaria, PV ;

Woodle, MC ;

Lu, P ;

Rouse, BT .

AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (06) :2177-2185

← 1 2 3 4 5 6 →